期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 177, 期 1, 页码 3-27出版社
WILEY
DOI: 10.1111/bph.14876
关键词
-
资金
- Applied Molecular Biosciences Unit - UCIBIO: FCT/MCTES [UID/Mult/04378/2019]
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
- Faculdade de Ciencias e Tecnologia, Universidade Nova de Lisboa [IF/00700/2014]
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [2015/17177-6, 2017/09022-8, 2017/17648-4]
- Ministerio da Saude [FNS/UnB TED42/2017, FNS/UnB TED74/2016]
- FCT/MCTES [UID/Multi/04378/2019]
- National Institute of Science and Technology INCTBioNat [465637/2014-0]
- ArboControl Brasil Project [FNS/UnB TED74/2016, TED42/2017]
- CNPQ
- FAPESP [2015/17177-6, 2017/09022-8, 2017/17648-4]
Marine natural products have proven, over the last half-century, to be effective biological modulators. These molecules have revealed new targets for cancer therapy as well as dissimilar modes of action within typical classes of drugs. In this scenario, innovation from marine-based pharmaceuticals has helped advance cancer chemotherapy in many aspects, as most of these are designated as first-in-class drugs. Here, by examining the path from discovery to development of clinically approved drugs of marine origin for cancer treatment-cytarabine (Cytosar-U (R)), trabectedin (Yondelis (R)), eribulin (Halaven (R)), brentuximab vedotin (Adcetris (R)), and plitidepsin (Aplidin (R))- together with those in late clinical trial phases-lurbinectedin, plinabulin, marizomib, and plocabulin-the present review offers a critical analysis of the contributions given by these new compounds to cancer pharmacotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据